Anti-inflammatory medicaments

An adduct comprising a molecule binding with a p 38-alpha kinase, said molecule having the formula

• A-T-(L)n-(NH)p-D-(E)q-(Y)t-Q (IB)
• wherein:
• Y is selected from the group consisting of —O—, —S—, —NR6—, —NR6SO2—, —NR6CO—, alkynyls, alkenyls, alkylenes, —O(CH2)h—, and —NR6(CH2)h—, where each h is individually selected from the group consisting of 1, 2, 3, or 4, and where for each of alkylenes, —O(CH2)h—, and —NR6(CH2)h—, one of the methylene groups present therein may be optionally double-bonded to a side-chain oxo group except that where —O(CH2)h— the introduction of the side-chain oxo group does not form an ester moiety;
• A is selected from the group consisting of aromatic, monocycloheterocyclic, and bicycloheterocyclic rings;
• and most preferably phenyl, naphthyl, pyridyl, pyrimidyl, thienyl, furyl, pyrrolyl, thiazolyl, isothiazolyl, oxaxolyl, isoxazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, benzimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, benzothienyl, pyrazolylpyrimidinyl, imidazopyrimidinyl, purinyl, and
• where each W1 is individually selected form the group consisting of —CH— and —N—.
• D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, thienyl, pyridyl, and pyrimidyl;
• E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;
• L is selected from the group consisting of —C(O)— and —S(O)2—;
• T is N6, O, alkylene, —O(CH2)h—, or —NR6(CH2)h—, where each h is individually selected from the group consisting of 1, 2, 3, or 4, or T is absent wherein A is directly bonded to -(L)n(NH)p-D-(E)q-(Y)t-Q;
• n is 0 or 1;
• p is 0 or 1;
• q is 0 or 1;
• t is 0 or 1;
• v is 1, 2, or 3;
• x is 1 or 2;
• Q is selected from the group consisting of formulae Q36-Q59, inclusive, said Q36-Q59 groups being selected from the group consisting of
• each R4 group is individually selected from the group consisting of —H, alkyls, aminoalkyls, alkoxyalkyls, aryls, aralkyls, heterocyclyls, and heterocyclylalkyls except when the R4 substituent places a heteroatom on an alpha-carbon directly attached to a ring nitrogen on Q;
• when two R4 groups are bonded with the same atom, the two R4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring;
• each R6 is individually selected from the group consisting of —H, alkyls, allyls, and B-trimethylsilylethyl;
• each R8 is individually selected from the group consisting of alkyls, phenyl, naphthyl, aralkyls, heterocyclyls, and heterocyclylalkyls;
• each R9 group is individually selected from the group consisting of —H, —F, and alkyls, wherein when two R9 groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;
• each R9, group is individually selected from the group consisting of —F, and alkyls, wherein when two R9, groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;
• each R10 is alkyl or perfluoroalkyl;
• G is alkylene, N(R6), O;
• and
• each Z is individually selected from the group consisting of —O— and —N(R4)—;
• and each ring of formula (IB) optionally includes one or more of R7′, where R7′ is a substituent individually selected from the group consisting of —H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, perfluoroalkoxys, aryloxys, alkylthios, arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfinyls, alkylsulfonyls, aminosulfonyls, perfluoroalkyls;
• aminooxaloylamino;
• alkylaminooxaloylamino;
• dialkylaminooxaloylamino;
• morpholinooxaloylamino;
• piperazinooxaloylamino;
• alkoxycarbonylamino;
• heterocyclyloxycarbonylamino;
• heterocyclylalkyloxycarbonylamino;
• heterocyclylcarbonylamino;
• heterocyclylalkylcarbonylamino;
• aminoalkyloxycarbonylamino;
• alkylaminoalkyloxycarbonylamino;
• or dialkylaminoalkyloxycarbonylamino,